FDA Freezes Long-Term Study on Diabetes Drug Avandia

This press release is an announcement submitted by CNN Health, and was not written by Diabetes Health.

Last week an FDA advisory panel recommended that Avandia not be sold without a stronger warning label or possibly limits on who could receive it.

Jul 23, 2010

A long-term study on the safety of a popular diabetes drug was put on hold Wednesday by the Food and Drug Administration, while the FDA considers whether it's too dangerous to continue.  Several large studies have linked the drug, Avandia, to a higher risk of heart attacks and other heart problems. While other studies have not found the same risk, last week an FDA advisory panel recommended that the drug not be sold without a stronger warning label or possibly limits on who could receive it.

The so-called TIDE trial was ordered by the FDA in 2007, after the first major study suggesting a link to heart trouble. It's designed to compare Avandia with Actos, a similar medication.  The study was the subject of impassioned argument at the two-day meeting last week. A prominent FDA official, Dr. David Graham, said it should be stopped because there was no true benefit to participants and that it amounted to "human exploitation."

"It's a study to establish harm," Graham told the panel. "If the purpose of a study is to establish harm, it's unethical right off the bat. You can do that to laboratory animals, but not to human beings."

Dr. Hertzel Gerstein, the lead investigator of TIDE study, defended the study, saying, "The protocol has been independently reviewed by hundreds of ethics committees around the world."

The FDA panel voted, 20-10, to recommend that the TIDE study continue.

GlaxoSmithKline (GSK), the company that sells Avandia, was supposed to recruit 16,000 patients for the TIDE study, but recruitment has been slower than expected. So far just 1,324 have signed up, spread around 353 medical centers in 23 countries, according to GSK spokeswoman Mary Anne Rhyne. Wednesday's decision allows patients already enrolled to continue in the study, but directs investigators to review the safety issues and what information they provide to patients.

"This pause in enrollment will give clinical trial investigators and patients time to learn about the data presented to the FDA Advisory Committee and the Committee's recommendations," GSK's chief medical officer Dr. Ellen Strahlman said in a statement.

The FDA is still weighing whether to take the panel's advice on a stronger warning label and tighter restrictions, and whether to go even further and pull the drug off the market. A spokeswoman said the TIDE decision was not a signal that the agency is leaning one way or another on those decisions.

* * *

Source: CNN Health


Click Here To View Or Post Comments

Categories: Diabetes, Diabetes, Food, Government & Policy, Health Research, Medications, Type 2 Issues, Type 2 Medications

Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12th Annual Product Reference Guide
  • Insulin Syringe Chart
  • Insulin Pen Needles Chart
  • Fast-Acting Glucose
  • Sharps Disposal
  • Blood Glucose Meters Chart
  • Insulin Pumps Chart
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...

Username: Password:
©1991-2015 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.